Investors: Novo Nordisk's obesity efforts will lead to growth
Obesity will continue to be a huge health problem, which means a lot of growth potential for the company, one analyst says.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
Danish firm Novo Nordisk's share price has experienced a boost on the stock exchange over the past few months, and the party is far from over.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk bets on RNA in several business areas
For subscribers
Launch of obesity drug will be Novo Nordisk's fastest ever
For subscribers
FDA approves Novo Nordisk's semaglutide as obesity treatment
For subscribers
.jpg&w=384&q=75)
